Czech National Bank Boosts Holdings in Eli Lilly and Company

Institutional investor increases stake in pharmaceutical giant by 3.7% in Q4

Mar. 28, 2026 at 8:07am

Got story updates? Submit your updates here. ›

The Czech National Bank, a major institutional investor, grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.7% during the fourth quarter of 2025, according to a recent filing with the Securities and Exchange Commission. The bank now owns 209,399 shares of the pharmaceutical company's stock, valued at approximately $225 million.

Why it matters

Eli Lilly is one of the world's largest and most influential pharmaceutical companies, with a diverse portfolio of blockbuster drugs. The Czech National Bank's increased investment signals confidence in the company's long-term growth prospects and ability to generate returns for shareholders.

The details

The Czech National Bank's holdings in Eli Lilly now make up 1.5% of its overall investment portfolio, making the stock its 12th largest holding. The institutional investor purchased an additional 7,480 shares of the company's stock during the fourth quarter. Eli Lilly's shares have seen strong performance in recent years, driven by the success of its newer drugs and the company's focus on innovation in areas like diabetes, oncology, and neuroscience.

  • The Czech National Bank increased its stake in Eli Lilly during the fourth quarter of 2025.

The players

Czech National Bank

A major institutional investor and central bank of the Czech Republic.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana, known for its innovative drug portfolio and focus on areas like diabetes, oncology, and neuroscience.

Got photos? Submit your photos here. ›

The takeaway

The Czech National Bank's increased investment in Eli Lilly underscores the pharmaceutical company's strong financial position and growth potential in the global market. As one of the world's leading institutional investors, the bank's move signals confidence in Eli Lilly's ability to continue delivering value for shareholders.